Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Decibel Therapeutics, Inc. DBTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
30/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Decibel Therapeutics, Inc. (DBTX) is a Biotechnology company in the Healthcare sector, currently trading at $4.91. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $63M (loss), growing at -16.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $14M against $82M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 4.81 (strong liquidity). Debt-to-assets is 11.4%. Total assets: $123M.

Analyst outlook: 4 / 7 analysts rate DBTX as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 40/100 (Partial), Income ?/100 (Fail).

DBTX SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DBTX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
DBTX: +0%/yr revenue is, -16.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet DBTX: Debt-to-Equity (D/E) ratio 0.17 (conservative), Current ratio is 4.81 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
DBTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 4 / 7 analysts rate DBTX as buy (57%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.61-5.4
Volume1.06M
Avg Volume (30D)214.74K
Market Cap$123.37M
Beta (1Y)-0.40
Share Statistics
EPS (TTM)-2.52
Shares Outstanding$24.96M
IPO Date2021-02-12
Employees68
CEOLaurence E. Reid
Financial Highlights & Ratios
EBITDA$-62.5M
Net Income$-63.01M
Operating Income$-63.96M
Total Cash$104.56M
Total Debt$14.05M
Net Debt$-20.55M
Total Assets$123.37M
Price / Earnings (P/E)-1.9
Analyst Forecast
Rating ConsensusBuy
Analysts Covering7
Buy 57% Hold 43% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS24343R1068

Price Chart

Track all markets on TradingView
DBTX
Decibel Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.61 52WK RANGE 5.40

People Also View

CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message